Washington Attorney General Nick Brown is urging consumers and businesses in the state to check whether they are eligible for compensation under a settlement ti
Washington Attorney General Nick Brown is urging consumers and businesses in the state to check whether they are eligible for compensation under a settlement tied to allegations that generic drug manufacturers conspired to inflate prices.
The U.S. District Court for the District of Connecticut recently granted preliminary approval of a plan to distribute settlement funds paid by generic drug manufacturers, following litigation brought by Washington and a coalition of 47 other states and territories. The coalition alleged the companies illegally conspired to raise generic drug prices.
“Washingtonians deserve fair pricing for the medications they need to stay healthy. This bipartisan agreement secures compensation for Washington consumers who were unlawfully overcharged,” Brown said. “Our antitrust team is committed to holding Big Pharma accountable and making sure corporations follow the law.”
The coalition previously announced settlements totaling approximately $96.5 million with manufacturers Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure.
A list of the included generic drugs can be found HERE.
Washingtonians who purchased a generic drug included on the settlement list between May 2009 and December 2019 may be eligible for compensation. To determine eligibility, consumers can call 1-866-290-0182, email info@AGGenericDrugs.com or visit AGGenericDrugs.com.
Washington and Idaho were the only states in the coalition that also secured restitution for businesses impacted by the alleged conspiracy.
Businesses in Washington that indirectly bought one or more of the generic prescription drugs at issue in the states’ cases, or provided reimbursement for some or all of the purchase price, may also be eligible for compensation for the period from May 2009 to December 2019.
Washington has been part of a coalition of nearly all states and territories pursuing a series of antitrust cases related to generic drug prices since 2016, with some cases still ongoing.
The cases stem from investigations that officials say were built on evidence from cooperating witnesses, millions of documents, and a large phone record database. Each complaint focuses on a different set of drugs and defendants, alleging an interconnected web of competing industry executives who regularly met and communicated, creating opportunities to form illegal agreements.
